Genmab | GEN - Assets


Genmab reported DKK12.52B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Almirall EUR 2.37B 29.97M Jun/2026
Amarin USD 624.36M 21.4M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
argenx SE USD 10.03B 1.35B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bayer EUR 107.29B 659M Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Demant DKK 40.03B 951M Jun/2026
Exelixis USD 2.49B 99.36M Jun/2026
Fresenius Medical Care EUR 31.29B 174.35M Jun/2026
Genmab DKK 12.52B 139M Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
GN Store Nord DKK 29.55B 996M Jun/2026
GRIFOLS EUR 20.09B 12M Jun/2026
Hikma Pharmaceutical USD 5.67B 117M Dec/2025
Insmed USD 2.1B 26.7M Jun/2026
Lakefront Biotherapeutics EUR 3.35B 21.24M Jun/2026
Lonza CHF 18.97B 164M Dec/2025
Merck EUR 52.69B 383M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sanofi EUR 129.06B 1.04B Jun/2026
UCB EUR 18.16B 971M Dec/2025